Huons Group looks to build on recent success
![Huons Global expects to take a leap forward as a global healthcare group [HUONS GLOBAL]](https://koreajoongangdaily.joins.com/data/photo/2022/03/22/65b9d5da-9993-4a01-a513-5fbcab0ddb33.jpg)
Huons Global expects to take a leap forward as a global healthcare group [HUONS GLOBAL]
Huons Global, the holding company of Huons Group, achieved sales of 575.6 billion won ($474 million) based on consolidated financial statements in 2021, posting 10 percent year-on-year growth.
The group is now focusing on its future growth engines through the conclusion of investment contracts and business expansion toward overseas markets.
Huons BioPharma, a fully-owned subsidiary of Huons Global, signed an export contract with the world’s largest botulinum toxin markets of the United States, China and Europe to supply its Hutox botulinum toxin for sale. The company is not only exporting its finished products, but also formed a future-oriented partnership in China, attracting large capital investment from its partnering company IMEIK.
Huons Group is strengthening collaboration with research and development bio ventures to secure long-term growth momentum for the future. Already this year, Humedix has signed a series of MOUs and contracts with R&D specialized companies such as GenNBio, HLB Pharma, Kineta and G2GBIO.
One related project focuses on sustained release injections, a new alternative that relieves the burden of drugs for patients with refractory diseases who have to take medication or injections every day. Humedix is planning to develop obesity treatments in cooperation with HLB Pharma, as well as developing sustained release injections targeting Alzheimer’s, diabetes and osteoarthritis with G2GBIO.
It has also invested $2 million in Kineta.
As interest in health-functional foods grows, Huons launched Huons Foodience in January to support the growth of the related business. Huons Foodience has completed a value chain that covers the whole process from development to production of functional raw materials, with a lineup of health-functional foods including red ginseng, multivitamins and probiotics.
It has succeeded in commercializing a health supplement named Elruby Menolacto Probiotics YT1 that helps improve the symptoms of the female menopause including hot flushes. Huons Foodience plans to lead a health-functional food business, in line with trends such as “Healthy Pleasure” and “Self-Medication.”
Huons Global has launched Huons Meditech by merging subsidiaries, Huons Medicare and Huons Medical. Huons Meditech plans to conduct synergistic marketing based on strengthened portfolios that embrace disinfection, sterilization and aesthetic treatment. It aims to become a leading medical company that sets global market trends for medical and healthcare devices.
Huons Group is also focusing on corporate sustainability management by integrating environmental, social and corporate governance (ESG) activities and proactively responding to various issues in line with global management trends.
“We plan to continue ESG management activities to promote the long-term value of Huons Group and sustainable growth in the future,” an official at Huons Group said. “We will grow into a global healthcare group that creates a healthy society.”
BY HAJIN KIM (kim.hajin@joongang.co.kr)
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)